Abbott Laboratories (ABT) News
Filter ABT News Items
ABT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ABT News Highlights
- For ABT, its 30 day story count is now at 21.
- Over the past 22 days, the trend for ABT's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- OG, SCS and DRUG are the most mentioned tickers in articles about ABT.
Latest ABT News From Around the Web
Below are the latest news stories about ABBOTT LABORATORIES that investors may wish to consider to help them evaluate ABT as an investment opportunity.
3 Dividend Stocks to Buy in September for Passive Income GenerationLots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. Here's how they could provide ever-increasing dividend payments to your brokerage account. Shares of Abbott Laboratories (NYSE: ABT) have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. |
Abbott (ABT) Gains As Market Dips: What You Should KnowIn the latest trading session, Abbott (ABT) closed at $102.65, marking a +0.44% move from the previous day. |
Top 10 Stock Picks of Robert B. Gillam’s McKinley Capital ManagementThis article discusses the top ten stock picks of Robert B. Gillam’s McKinley Capital Management at the end of the second quarter. You can skip our detailed analysis of the hedge fund’s performance and its investment strategy, and go directly to read Top 5 Stock Picks of Robert B. Gillam’s McKinley Capital Management. Bob Gillam, […] |
New Data Show Abbott's HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure PatientsAbbott (NYSE: ABT) today announced new late-breaking data that show its HeartMate 3™ heart pump extends survival of advanced heart failure patients by at least five years, providing a clear life-saving option for people battling later stage disease. The data are from the MOMENTUM 3 trial, the world's largest randomized clinical trial to assess long-term outcomes in people receiving a left ventricular assist device (known as an LVAD, or heart pump) to treat advanced heart failure. The data were p |
Abbott restarts Similac infant formula production at Michigan facilityAbbott, the biggest U.S. supplier of baby formula, in February recalled Similac and other infant formula products produced at the Michigan facility after reports of bacterial infections in babies who had consumed products that originated there. The plant shutdown and subsequent product recall deepened a supply shortage in a nation where less than half of babies are exclusively breast-fed through their first three months, according to federal data from 2020. |
CORRECTED-Abbott restarts Similac infant formula production at Michigan facilityAbbott Laboratories has restarted production of its Similac infant formula at the plant in Sturgis, Michigan at the center of the U.S. baby formula shortage. Abbott, the biggest U.S. supplier of baby formula, in February recalled Similac and other infant formula products produced at the Michigan facility after reports of bacterial infections in babies who had consumed products that originated there. |
Abbott (ABT) Gains But Lags Market: What You Should KnowAbbott (ABT) closed the most recent trading day at $105.89, moving +0.43% from the previous trading session. |
Abbott (ABT) to Offer New Treatment Option for Chronic PainAbbott's (ABT) Proclaim Plus SCS system with FlexBurst360 therapy will cater to the changing needs of patients with chronic pain. |
The Best Stocks to Invest $5,000 in Right NowNo list of great companies to invest in will satisfy everyone, but Abbott Laboratories (NYSE: ABT) and Microsoft (NASDAQ: MSFT) are stocks worth watching. Abbott Laboratories is one of the most notable medical device companies around. Although past history is no guarantee of future success, Abbott Laboratories' business remains healthy, as revenue and profits continue growing despite the headwinds it encountered earlier this year. |
UPDATE 2-U.S. to extend baby formula waivers for poor families through year-endThe Biden administration will extend through year end waivers that make it easier for low-income families to access baby formula through a government program, the U.S. Department of Agriculture (USDA) plans to announce on Tuesday. Earlier this year, the USDA started covering the difference in costs for states to offer a broader range of infant formula products for low-income families, after the closure of Abbott Laboratories' Michigan plant exacerbated a national shortage of the vital product. The current waivers are set to expire on Sept. 30 and the extension will help the government avoid a steep drop in infant formula access as shortages linger in pockets across the country. |